Study of XL820 in Adults With Solid Tumors

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of XL820 Administered Orally to Subjects With Solid Tumors

The purpose of this study is to assess the safety and tolerability of XL820 when given orally to adults with advanced solid tumors.

Inclusion Criteria:

• Advanced solid tumor
• Cancer for which standard therapies do not exist or are no longer effective
• Life expectancy of > 3 months
• Adequate bone marrow, liver, and kidney function
• Willing to use accepted method of contraception during the course of the study
• Negative pregnancy test (females)
• Written informed consent

Exclusion Criteria:

• Chemotherapy within 4-6 weeks of the start of treatment (depending on the therapy)
• Radiotherapy to more than 25% of bone marrow within 4 weeks of the start of treatment
• Investigational drug within 30 days of the start of treatment
• Subjects with known brain metastasis
• Uncontrolled medical disorder such as infection or cardiovascular disease
• Subjects known to be HIV positive
• Pregnant or breastfeeding women